RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Patiromer Controls RAASi-Associated HK in Patients with Diabetes and CKD
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 14
IS 49
SP 13
OP 14
DO 10.1177/155989771449008
UL http://mdc.sagepub.com/content/14/49/13.abstract
AB Renin-angiotensin-aldosterone system inhibitors (RAASis) are beneficial and recommended for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, hyperkalemia (HK) often limits RAASi therapy. The OPAL-HK [NCT01810939] trial found that patiromer normalized serum potassium (s-K+) and prevent HK recurrence compared with placebo. This article discusses a poster investigating the prespecified analysis of the subgroup with T2DM in OPAL-HK.